These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25904511)

  • 21. Military brings order to formulary system.
    Berberabe T
    Manag Care; 2004 Nov; 13(11):28-30. PubMed ID: 15595398
    [No Abstract]   [Full Text] [Related]  

  • 22. Ethical considerations.
    Treiman DM
    Epilepsy Res Suppl; 1993; 10():137-48. PubMed ID: 8251089
    [No Abstract]   [Full Text] [Related]  

  • 23. COX-2 inhibitors--lessons in drug safety.
    Psaty BM; Furberg CD
    N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
    [No Abstract]   [Full Text] [Related]  

  • 24. A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.
    Kashoki M; Hanaizi Z; Yordanova S; Veselý R; Bouygues C; Llinares J; Kweder SL
    Clin Pharmacol Ther; 2020 Jan; 107(1):195-202. PubMed ID: 31306483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory review of novel therapeutics--comparison of three regulatory agencies.
    Downing NS; Aminawung JA; Shah ND; Braunstein JB; Krumholz HM; Ross JS
    N Engl J Med; 2012 Jun; 366(24):2284-93. PubMed ID: 22591257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneity in search strategies among Cochrane acupuncture reviews: is there room for improvement?
    Lui S; Smith EJ; Terplan M
    Acupunct Med; 2010 Sep; 28(3):149-53. PubMed ID: 20615852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatory science as a bridge between science and society.
    Tominaga T; Asahina Y; Uyama Y; Kondo T
    Clin Pharmacol Ther; 2011 Jul; 90(1):29-31. PubMed ID: 21691273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Translational medicine].
    Antal J; Timár A
    Orv Hetil; 2011 Nov; 152(47):1894-902. PubMed ID: 22042316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paving roads for new drugs in oncology.
    Zaenker KS; Entschladen F
    Recent Pat Anticancer Drug Discov; 2009 Jun; 4(2):137-45. PubMed ID: 19519536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electronic publishing. DOE cites competition in killing PubSCIENCE.
    Seife C
    Science; 2002 Aug; 297(5585):1257-9. PubMed ID: 12193762
    [No Abstract]   [Full Text] [Related]  

  • 31. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States.
    Zaim R; Redekop K; Uyl-de Groot CA
    J Cancer Policy; 2022 Sep; 33():100346. PubMed ID: 35779788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches.
    Royle P; Milne R
    Int J Technol Assess Health Care; 2003; 19(4):591-603. PubMed ID: 15095765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An encouraging assessment of methods to inform priorities for updating systematic reviews.
    Sutton AJ; Donegan S; Takwoingi Y; Garner P; Gamble C; Donald A
    J Clin Epidemiol; 2009 Mar; 62(3):241-51. PubMed ID: 18783919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Not Available].
    Banzi R
    Recenti Prog Med; 2019 Nov; 110(11):526-527. PubMed ID: 31808433
    [No Abstract]   [Full Text] [Related]  

  • 36. Producing and disseminating systematic reviews: a summary of the CAM-related work presented at the 13th international Cochrane Colloquium.
    Manheimer E; Berman B
    J Altern Complement Med; 2006 Mar; 12(2):193-6. PubMed ID: 16566681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
    Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
    BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An evaluation of search and selection methods used in dental systematic reviews published in English.
    Major MP; Major PW; Flores-Mir C
    J Am Dent Assoc; 2006 Sep; 137(9):1252-7. PubMed ID: 16946429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses.
    Hart B; Lundh A; Bero L
    BMJ; 2012 Jan; 344():d7202. PubMed ID: 22214754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
    Roberts SA; Allen JD; Sigal EV
    Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.